期刊
ACS MEDICINAL CHEMISTRY LETTERS
卷 4, 期 7, 页码 110-114出版社
AMER CHEMICAL SOC
DOI: 10.1021/ml400088y
关键词
Mycobacterium tuberculosis; imidazo[1,2-a]pyridine-3-carboxamides; MDR-TB; XDR-TB; pharmacokinetics
资金
- NIH [AI054193]
- Dow AgroSciences
- NSF [CHE-0741793]
A set of 14 imidazo[1,2-a]pyridine-3-carboxamides was synthesized and screened against Mycobacterium tuberculosis H(37)Rv. The minimum inhibitory concentrations of 12 of these agents were <= 1 mu M against replicating bacteria and 5 compounds (9, 12, 16, 17, and 18) had MIC values <= 0.006 mu M. Compounds 13 and 18 were screened against a panel of MDR and XDR drug resistant clinical Mtb strains with the potency of 18 surpassing that of clinical candidate PA-824 by nearly 10-fold. The in vivo pharmacokinetics of compounds 13 and 18 were evaluated in male mice by oral (PO) and intravenous (IV) routes. These results indicate that readily synthesized imidazo[1,2-a]pyridine-3-carboxamides are an exciting new class of potent, selective anti-TB agents that merit additional development opportunities.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据